Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–62. https://doi.org/10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6. PMID: 36084663.

Article  CAS  PubMed  Google Scholar 

Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2017;19(1):3–9. https://doi.org/10.1016/j.hpb.2016.10. Epub 2016 Oct 27. PMID: 28341429.

Article  PubMed  Google Scholar 

Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, Yuen J, Poon RTP, Fan ST, Lo CM. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104(13):1775–84. Epub 2017 Nov 1. PMID: 29091283.

Article  CAS  PubMed  Google Scholar 

Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019;70(5):866–73. Epub 2019 Jan 5. PMID: 30615906.

Article  PubMed  Google Scholar 

Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–65. https://doi.org/10.1097/HEP.0000000000000466. Epub 2023 May 22. Erratum in: Hepatology. 2023;: PMID: 37199193; PMCID: PMC10663390.

Article  PubMed  Google Scholar 

Marinelli B, Kim E, D’Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022;10(6):e004205. https://doi.org/10.1136/jitc-2021-004205. PMID: 35710293; PMCID: PMC9204420.

Article  PubMed  PubMed Central  Google Scholar 

Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914–21. https://doi.org/10.1111/j.1572-0241.2007.01712.x. Epub 2008 Jan 2. PMID: 18177453.

Article  PubMed  Google Scholar 

Wang Y, Li M, Zhang Z, Gao M, Zhao L. Application of Radiomics in the efficacy evaluation of Transarterial Chemoembolization for Hepatocellular Carcinoma: a systematic review and Meta-analysis. Acad Radiol. 2024;31(1):273–85. Epub 2023 Sep 9. PMID: 37684182.

Article  PubMed  Google Scholar 

Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682–720. doi: 10.1159/000509424. Epub 2020 Nov 11. PMID: 33442540; PMCID: PMC7768108.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1. PMID: 29433850.

Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L, Fan W. Efficacy of apatinib in transcatheter arterial chemoembolization (TACE) refractory Intermediate and Advanced-Stage Hepatocellular carcinoma: a propensity score matching analysis. Cancer Manag Res. 2019;11:9321–30. PMID: 31802950; PMCID: PMC6830366.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Liu D, Wang C, Yu S, Jin G, Wang C, Zhang B, Zhang D, Shao D. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: a real-world study. Clin Res Hepatol Gastroenterol 2022 Jun-Jul;46(6):101869. https://doi.org/10.1016/j.clinre.2022.101869. Epub 2022 Jan 31. PMID: 35108656.

Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial Chemoembolization (TACE) combined with Sorafenib versus TACE alone for Unresectable Hepatocellular Carcinoma: a propensity score matching study. J Cancer. 2019;10(5):1189–96. https://doi.org/10.7150/jca.28994. PMID: 30854128; PMCID: PMC6400692.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang JX, Hua HJ, Cheng Y, Liu S, Shi HB, Zu QQ. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis. Acad Radiol. 2023 Sep 27:S1076-6332(23)00469-5. doi: 10.1016/j.acra.2023.09.001. Epub ahead of print. PMID: 37775449.

Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget. 2016;7(50):83806–16. https://doi.org/10.18632/oncotarget.11514. PMID: 27566566; PMCID: PMC5347807.

Article  PubMed  PubMed Central  Google Scholar 

Gu H, Li J, You N, Wu K, Wang Z, Wang L, Zhu Y, Liu Q, Peng X, Zheng L. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma. Ann Transl Med. 2020;8(24):1677. https://doi.org/10.21037/atm-20-7244. PMID: 33490189; PMCID: PMC7812192.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL. KEYNOTE-240 investigators. Pembrolizumab as Second-Line therapy in patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: a Randomized, Double-Blind, phase III trial. J Clin Oncol. 2020;38(3):193–202. Epub 2019 Dec 2. PMID: 31790344.

Article  CAS  PubMed  Google Scholar 

Montasser A, Beaufrère A, Cauchy F, Bouattour M, Soubrane O, Albuquerque M, Paradis V. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology. 2021;79(1):36–46. https://doi.org/10.1111/his.14317. Epub 2021 Mar 28. PMID: 33326644.

Article  PubMed  Google Scholar 

Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in Advanced Hepatocellular Carcinoma. Cancers (Basel). 2020;12(5):1089. https://doi.org/10.3390/cancers12051089. PMID: 32349374; PMCID: PMC7281246.

Article  CAS  PubMed  Google Scholar 

Chen S, Wu Z, Shi F, Mai Q, Wang L, Wang F, Zhuang W, Chen X, Chen H, Xu B, Lai J, Guo W. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol. 2022;148(8):2115–25. Epub 2021 Aug 28. PMID: 34453221; PMCID: PMC9293824.

Article  CAS  PubMed  Google Scholar 

Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, Zhou J, Zhu K. Transarterial Chemoembolization Combined with Lenvatinib Plus PD-1 inhibitor for Advanced Hepatocellular Carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387. https://doi.org/10.3389/fimmu.2022.848387. PMID: 35300325; PMCID: PMC8921060.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang WJ, Liu ZH, Wang K, Yu HM, Cheng YQ, Xiang YJ, Feng JK, Zhou LP, Zhou HK, Pan WW, Guo WX, Shi J, Cheng SQ. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: a multicenter, retrospective study. Cancer Med. 2023;12(10):11513–24. Epub 2023 Mar 31. PMID: 36999793; PMCID: PMC10242311.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26. PMID: 32112738.

Song H, Liu X, Jiang L, Li F, Zhang R, Wang P. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1. Recent Pat Anticancer Drug Discov. 2021;16(3):312–332. https://doi.org/10.2174/1574892816666210208231744. PMID: 33563158.

Duan X, Li H, Kuang D, Chen P, Zhang K, Li Y, He X, Xing C, Wang H, Liu Y, Xie L, Zhang S, Zhang Q, Zhu P, Dong H, Xie J, Li H, Wang Y, Shi M, Jiang G, Xu Y, Zhou S, Shang C, Ren J, Han X. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. Hepatol Int. 2023;17(4):915–26. https://doi.org/10.1007/s12072-023-10519-8. Epub 2023 Apr 3. PMID: 37012542; PMCID: PMC10386927.

Article  PubMed  Google Scholar 

Chan SL, Wong N, Lam WKJ, Kuang M. Personalized treatment for hepatocellular carcinoma: current status and future perspectives. J Gastroenterol Hepatol. 2022;37(7):1197–206. https://doi.org/10.1111/jgh.15889. Epub 2022 May 25. PMID: 35570200.

Article  PubMed  Google Scholar 

Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. https://doi.org/10.1002/hep.24199. PMID: 21374666; PMCID: PMC3084991.

Article  PubMed  Google Scholar 

Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72(2):288–306. https://doi.org/10.1016/j.jhep.2019.09.026. PMID: 31954493.

Zhou Q, Wang X, Li R, Wang C, Wang J, Xie X, Li Y, Li S, Mao X, Liang P. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis. J Gastroenterol. 2022;57(9):684–694. https://doi.org/10.1007/s00535-022-01895-3. Epub 2022 Jul 11. Erratum in: J Gastroenterol. 2022;: PMID: 35816221; PMCID: PMC9392709.

Zhou Y, Sui C, Li B, Yin Z, Tan Y, Yang J, Liu Z. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J Surg Oncol. 2010;8:55. https://doi.org/10.1186/1477-7819-8-55. PMID: 20591196; PMCID: PMC2904292.

Article  PubMed  PubMed Central  Google Scholar 

Yamashita Y, Yoshida Y, Kurihara T, Itoh S, Harimoto N, Ikegami T, Yoshizumi T, Uchiyama H, Shirabe K, Maehara Y. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: repeat hepatectomy versus salvage living donor liver transplantation. Liver Transpl. 2015;21(7):961–8. https://doi.org/10.1002/lt.24111. Epub 2015 May 4. PMID: 25772591.

Article  PubMed  Google Scholar 

Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol. 2023;15(1):1–18. https://doi.org/10.4251/wjgo.v15.i1.1. PMID: 36684055; PMCID: PMC9850755.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng Z, Chen S, Wei M, Lin M, Jiang C, Mei J, Li B, Wang Y, Li J, Xie X, Chen M, Qian G, Kuang M. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology. 2018;287(2):705–714. https://doi.org/10.1148/radiol.2018171541. Epub 2018 Feb 1. PMID: 29390197.

Li Z, Han N, Ren X, Zhang Y, Chu X. Effectiveness of TKI inhibitors combined with PD-1 in patients with postoperative early recurrence of HCC: a real-world study. Front Oncol. 2022;12:833884. https://doi.org/10.3389/fonc.2022.833884. PMID: 35433466; PMCID: PMC9008361.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z, Yang Y. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol. 2022;77(6):1515–24. Epub 2022 Aug 18. PMID: 35985545.

Article  CAS  PubMed  Google Scholar 

Ma XL, Qu XD, Yang WJ, et al. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clin Chim Acta. 2020;511:67–74. https://doi.org/10.1016/j.cca.2020.09.026.

Article  CAS  PubMed